Product image of Nintedanib Ratiopharm (Nintedanib) supplied by GNH India

Nintedanib Ratiopharm

Active Ingredient:
Nintedanib
Origin:
EU

Nintedanib Ratiopharm (Nintedanib)

Nintedanib, the active ingredient in Nintedanib Ratiopharm, is a tyrosine kinase inhibitor presented as a 100 mg capsule for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and is used in combination therapy for non‑small cell lung cancer in appropriate patients.

GNH India supplies Nintedanib Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Teva Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nintedanib is indicated for fibrotic lung disorders and as part of combination therapy for certain lung cancers.

  • Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function.
  • Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and delays worsening.
  • Non‑small cell lung cancer (in combination therapy): enhances treatment efficacy when combined with chemotherapy.

How It Works

  • Nintedanib inhibits multiple receptor tyrosine kinases—including vascular endothelial growth factor receptors (VEGFR), platelet‑derived growth factor receptors (PDGFR), and fibroblast growth factor receptors (FGFR). By blocking these pathways, it reduces fibroblast proliferation, angiogenesis, and extracellular matrix deposition, thereby limiting fibrotic tissue formation and tumor‑related vascular growth.

Side Effects

Nintedanib may cause a range of adverse reactions.

Common Side Effects

  • Diarrhea: frequent loose stools, often mild to moderate.
  • Nausea: sensation of unease or urge to vomit.
  • Vomiting: expulsion of stomach contents.
  • Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects

  • Elevated liver enzymes: may indicate hepatic injury.
  • Bleeding events: increased risk of gastrointestinal or other bleeding.
  • Arterial thromboembolic events: potential for clot formation in arteries.
  • Gastrointestinal perforation: rare but severe tearing of the GI tract.

Precautions & Warnings

Before initiating therapy, several safety considerations should be addressed.

  • Liver function monitoring: assess baseline enzymes and repeat periodically.
  • Bleeding risk assessment: evaluate concomitant anticoagulant or antiplatelet use.
  • Cardiovascular evaluation: screen for history of arterial thrombotic disease.
  • Gastrointestinal symptom counseling: advise patients to report severe abdominal pain or persistent diarrhea.
  • Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Nintedanib can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure.
  • Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
  • Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased gastrointestinal toxicity risk.

Frequently Asked Questions

Nintedanib Ratiopharm is prescribed for idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and as part of combination therapy for non‑small cell lung cancer. In each case, the drug aims to slow disease progression by targeting pathways involved in fibrosis and tumor angiogenesis.

Nintedanib blocks several receptor tyrosine kinases—VEGFR, PDGFR, and FGFR—thereby inhibiting fibroblast growth, angiogenesis, and extracellular matrix production. This multi‑target inhibition reduces fibrotic tissue formation in the lungs and can limit tumor‑related blood vessel development when used with chemotherapy.

The specific dose and dosing schedule of Nintedanib Ratiopharm are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of Nintedanib in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider before using the medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Nintedanib differs from other antifibrotics such as pirfenidone by targeting a broader range of tyrosine kinases (VEGFR, PDGFR, FGFR). This multi‑kinase inhibition may offer benefits in certain fibrotic lung diseases and in combination cancer regimens, while the safety profile and tolerability can vary between agents.

Nintedanib Ratiopharm capsules should be stored at temperatures below 25 °C. Keep them in the original packaging to protect from moisture and light, and store them out of reach of children.

The medication is taken orally as a capsule, usually with food to reduce gastrointestinal discomfort. Patients should swallow the capsule whole with water and follow the dosing schedule prescribed by their healthcare professional.

Serious risks include elevated liver enzymes indicating possible hepatic injury, significant bleeding events, arterial thromboembolic complications, and rare gastrointestinal perforations. Patients should be monitored regularly for these events and report any unusual symptoms promptly.

Nintedanib is contraindicated in patients with known hypersensitivity to the active substance or any of the excipients. It should also be avoided in individuals with active severe liver disease, uncontrolled bleeding disorders, or recent major arterial thrombotic events unless specifically directed by a specialist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nintedanib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT